Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

Université de Montréal

$27,000.00

Translational success in corneal regenerative medicine: rates, barriers, and predictive factors

EF 2025-26

Résumé
Approximately 13 million people globally are blind as a result of corneal disease, but few patients have access to sight-saving corneal transplantation since donor tissue is in short supply. Novel regenerative strategies for corneal restoration are being developed, but the vast majority have yet to be translated to the clinic. The reasons why some therapies progress to the clinic, and many do not, are still not well understood. The objective of this study is to map the landscape of emerging corneal regenerative therapies, to identify factors that facilitate or impede translation to human therapies, and to capture the experiences of those at the forefront of corneal regenerative research and translation. We will conduct a systematic analysis of the published literature to understand how therapies transition from basic discovery through clinical trials to regulatory approval. We will investigate the factors that are predictive of translational success, and we will explore corneal researchers’ perspectives to elucidate the obstacles and facilitators they experience. Our outcomes will provide a clear picture of the current state of translation in corneal regenerative medicine, including bottlenecks, barriers and factors predictive of success, which will serve to eventually develop a novel approach to evaluate the translational potential of corneal regenerative therapies. This resource will help researchers and funders to prioritize and invest in the most promising therapies and accelerate their translation to the patients who need them.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573094
Name
Das Amrit
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Translational success in corneal regenerative medicine: rates, barriers, and predictive factors
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Clinical Translation; Corneal Blindness; Emerging Technologies; Regenerative Medicine; Translational Potential
Abstract
Approximately 13 million people globally are blind as a result of corneal disease, but few patients have access to sight-saving corneal transplantation since donor tissue is in short supply. Novel regenerative strategies for corneal restoration are being developed, but the vast majority have yet to be translated to the clinic. The reasons why some therapies progress to the clinic, and many do not, are still not well understood. The objective of this study is to map the landscape of emerging corneal regenerative therapies, to identify factors that facilitate or impede translation to human therapies, and to capture the experiences of those at the forefront of corneal regenerative research and translation. We will conduct a systematic analysis of the published literature to understand how therapies transition from basic discovery through clinical trials to regulatory approval. We will investigate the factors that are predictive of translational success, and we will explore corneal researchers’ perspectives to elucidate the obstacles and facilitators they experience. Our outcomes will provide a clear picture of the current state of translation in corneal regenerative medicine, including bottlenecks, barriers and factors predictive of success, which will serve to eventually develop a novel approach to evaluate the translational potential of corneal regenerative therapies. This resource will help researchers and funders to prioritize and invest in the most promising therapies and accelerate their translation to the patients who need them.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Das, Amrit
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~